journal
MENU ▼
Read by QxMD icon Read
search

Oncology (Williston Park, NY)

journal
https://www.readbyqxmd.com/read/28812305/point-should-radiation-therapy-after-surgery-for-ductal-carcinoma-in-situ-be-standard-practice
#1
Camille Berriochoa, Carisa Bohnak, Nicole Chahine, Chirag Shah
No abstract text is available yet for this article.
August 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28812304/management-of-castration-resistant-taxane-resistant-prostate-cancer
#2
Tomasz M Beer
Metastatic castration-resistant prostate cancer that is progressing despite docetaxel chemotherapy is difficult to treat and often aggressive. If not previously used, modern androgen signaling inhibitors have established clinical activity in this setting. Cabazitaxel and radium-223 have also been shown to extend survival in appropriately selected patients. Carboplatin-containing chemotherapy regimens have not been studied in randomized trials with a survival endpoint, but they have demonstrated activity in phase II trials and are occasionally considered in the post-docetaxel setting...
August 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28812303/circulating-tumor-dna-as-a-liquid-biopsy-current-clinical-applications-and-future-directions
#3
REVIEW
Kimberly M Komatsubara, Adrian G Sacher
Tumor genomic sequencing has become part of routine oncology practice in many tumor types, in order to identify potentially targetable mutations and to personalize cancer care. Plasma genotyping via circulating tumor DNA analysis is a noninvasive and rapid alternative method of detecting and monitoring genomic alterations throughout the course of disease. Multiple assays have been developed to date, each with different test characteristics and degrees of clinical validation. Here we review the clinical data supporting these different plasma genotyping methodologies, and present a practical approach to the interpretation of the results of these tests...
August 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28812302/management-of-sleep-wake-disturbances-comorbid-with-cancer
#4
Ann M Berger, Ellyn E Matthews, Ashley M Kenkel
It is critical that clinicians and healthcare systems adopt routine screening and affordable interventions to reduce chronic insomnia and improve the quality of life in cancer patients and survivors. We provide expert clinical advice on how to manage sleep-wake disturbances that occur comorbidly with cancer. Our discussion focuses on the etiology, screening, and assessment of sleep-wake disturbances, and on both nonpharmacologic and pharmacologic interventions to manage sleep disturbances, insomnia, and sleep-related breathing disorders...
August 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28812301/changing-treatment-paradigms-for-brain-metastases-from-melanoma-part-1-diagnosis-prognosis-symptom-control-and-local-treatment
#5
REVIEW
Vyshak Alva Venur, Pauline Funchain, Rupesh Kotecha, Samuel T Chao, Manmeet S Ahluwalia
Melanoma is the third most common cause of brain metastases, after lung and breast cancer. The management of melanoma brain metastases can be broadly divided into symptom control and therapeutic strategies. Supportive treatments include corticosteroids to reduce peritumoral edema, antiepileptics for seizure control, and medications to preserve cognitive function. Until recently, therapeutic strategies consisted primarily of local treatments, including surgery, whole-brain radiation therapy (WBRT), and stereotactic radiosurgery (SRS)...
August 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28812300/fay-hlubocky-on-recognizing-and-addressing-clinician-burnout
#6
Fay Hlubocky
No abstract text is available yet for this article.
August 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712102/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-2-approaches-beyond-first-line-therapy-and-novel-biologic-agents-under-investigation
#7
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
A frequent quandary for oncologists is the selection of chemotherapy and biologic therapy for patients with metastatic colorectal cancer in second-line and higher treatment settings. While not approved by the US Food and Drug Administration (FDA) in the first-line setting, the vascular endothelial growth factor (VEGF)-targeting agents ziv-aflibercept and ramucirumab are appropriate treatment options in the second-line setting, as is continuation of first-line bevacizumab. Tumor RAS mutational status is helpful to determine which patients may benefit from epidermal growth factor receptor (EGFR)-directed therapies, and other novel biomarkers (BRAF, HER2, and mismatch repair deficiency) allow us to select patients who may benefit from biologic therapies that are FDA-approved for other malignancies...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712101/molecular-profiling-in-the-practice-of-radiation-oncology
#8
Brian Marples, Alan Pollack
No abstract text is available yet for this article.
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712100/the-role-of-genomic-techniques-in-predicting-response-to-radiation-therapy
#9
REVIEW
Noelle L Williams, Tu Dan, Nicholas G Zaorsky, Shivank Garg, Robert B Den
The understanding of the relationship between genetic variation and an individual patient's response to radiation therapy (RT) has gained significant ground over the past several years. Genetic markers have been identified that could ultimately serve as the foundation for predictive models in clinical practice, and that hold the potential to revolutionize the delivery of precision medicine in oncology. Single nucleotide polymorphisms, single genes, and/or gene signatures could ultimately serve as the basis for patient stratification in prospective clinical trials...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712099/don-t-be-fooled-by-dcis
#10
Regina J Brown, Sharon Sams, Dulcy E Wolverton, Tae Chong, Virginia F Borges, Rachel A Rabinovitch, Colleen D Murphy
No abstract text is available yet for this article.
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712098/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-1-biologic-therapies-targeting-the-epidermal-growth-factor-receptor-and-vascular-endothelial-growth-factor
#11
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
The survival of patients with metastatic colorectal cancer has improved dramatically in recent years, with overall survival exceeding 3 years in large randomized clinical trials. There are now several treatment options for patients with metastatic colorectal cancer. In addition to chemotherapy backbones utilizing fluoropyrimidine, oxaliplatin, and irinotecan combinations, biologic agents that target specific oncogenic pathways have contributed to the improved survival observed in this patient population. This class of medications includes epidermal growth factor receptor (EGFR)-targeted drugs (cetuximab and panitumumab) and vascular endothelial growth factor (VEGF)-targeted therapies (bevacizumab, ramucirumab, ziv-aflibercept, and regorafenib)...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712097/fertility-preservation-in-young-adult-patients-with-cancer
#12
Joanne Frankel Kelvin
More than 60,000 young adults are diagnosed with cancer each year in the United States. Many will not have started or completed their families at the time of diagnosis, and reproductive concerns are common. Practice guidelines from a number of professional organizations, including the American Society of Clinical Oncology, highlight the need for oncology clinicians to address fertility with their at-risk patients by discussing options for fertility preservation. Fertility preservation options for men include sperm banking (through manual stimulation, electroejaculation, and testicular sperm extraction) and testicular shielding...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712096/myeloproliferative-neoplasms-translating-new-discoveries-into-better-outcomes-better-quality-of-life
#13
REVIEW
Leslie Padrnos, Ruben A Mesa
Despite the identification of JAK mutations and the development of targeted inhibitors, there remain significant unmet needs for patients with myeloproliferative neoplasms. Identification of the myeloproliferative neoplasm populations not currently benefiting from JAK inhibitor therapy highlights the therapeutic deficits still present in this heterogeneous stem cell malignancy. While JAK inhibition has provided significant benefits for patients with intermediate-2 or high-risk myelofibrosis and in patients with polycythemia vera in the second-line setting, JAK inhibitor monotherapy is not approved and not appropriate for all patients with myeloproliferative neoplasms...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712095/jeffrey-vacirca-on-how-the-coa-advocates-for-community-oncology-practices-and-patients
#14
Jeffrey Vacirca
No abstract text is available yet for this article.
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28620906/management-of-primary-mediastinal-b-cell-lymphoma-and-gray-zone-lymphoma
#15
Kieron Dunleavy
Primary mediastinal B-cell lymphoma is a distinct clinicopathologic entity that has a predilection for young women. It is clinically and molecularly different from other subtypes of diffuse large B-cell lymphoma and has a unique paradigm of management. While the cure rate for patients with primary mediastinal B-cell lymphoma is high, approaches have historically included mediastinal radiation; in moving therapeutics forward, strategies that obviate the need for radiation while maintaining high cure rates are critical...
June 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28620905/stereotactic-body-radiation-therapy-as-an-alternative-to-surgery-in-early-stage-non-small-cell-lung-cancer
#16
REVIEW
Kenneth Rosenzweig
Stereotactic body radiation therapy (SBRT) is a novel radiation technique that allows a high dose of radiation to be delivered to a tumor with relatively low dose to the surrounding normal tissue. SBRT has achieved extraordinary clinical success in patients with inoperable early-stage non-small-cell lung cancer (NSCLC). Local control of approximately 90% at 2 to 5 years has been demonstrated in multiple trials. In comparisons with surgical resection (in patients who are fit candidates for surgery), SBRT has provided similar local control, but was associated with worse survival, probably due to differences in the underlying patient populations...
June 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28620904/nonpalpable-intratesticular-mass-in-a-young-man-with-a-history-of-contralateral-retractile-testis
#17
J Ryan Mark, Leonard G Gomella
No abstract text is available yet for this article.
June 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28620903/emerging-categories-of-disease-in-advanced-prostate-cancer-and-their-therapeutic-implications
#18
REVIEW
Rahul R Aggarwal, Felix Y Feng, Eric J Small
The treatment of advanced prostate cancer has changed significantly in the last decade, as a result of the introduction of multiple new systemic therapies that have had a positive impact on treatment outcomes. The increasing number of therapies, along with new insights into the biological underpinnings of prostate cancer, have led to a growing appreciation for the heterogeneity of the disease and an awareness of emerging subcategories that have direct therapeutic implications for the practicing clinician. In the metastatic hormone-naive setting, the extent of metastatic disease visible on scans can serve as a useful measure to guide treatment decisions; the addition of docetaxel chemotherapy to hormonal therapy has significant benefit in patients whose scans show more extensive disease...
June 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28620902/counterpoint-primary-debulking-surgery-vs-neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer
#19
Anna Fagotti, Giovanni Scambia
No abstract text is available yet for this article.
June 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28620901/point-primary-debulking-surgery-vs-neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer
#20
Renee A Cowan, Dennis S Chi
No abstract text is available yet for this article.
June 15, 2017: Oncology (Williston Park, NY)
journal
journal
29689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"